Breaking News Instant updates and real-time market news.

PBYI

Puma Biotechnology

$38.05

1.35 (3.68%)

16:21
03/01/17
03/01
16:21
03/01/17
16:21

Puma Biotechnology reports Q4 adjusted EPS ($1.22), consensus ($1.92)

Reports Q4 R&D expenses $56.4M vs $52.5M last year. "We made significant progress with the neratinib clinical program during the fourth quarter," said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. "We presented additional results of several ongoing studies at the 2016 San Antonio Breast Cancer Symposium, including our Phase II CONTROL trial of PB272 in the extended adjuvant treatment of HER2-positive early stage breast cancer; a biomarker analysis of the NSABP FB-7 Phase II trial for the neoadjuvant treatment of HER2-positive locally advanced breast cancer; and the Phase II SUMMIT trial of PB272 for ERBB2 mutant, HER2 non-amplified metastatic breast cancer. We also initiated a Managed Access Program for PB272 outside the United States, providing physicians and patients access to PB272 when there are limited or no other therapeutic options available."

  • 21

    Jul

PBYI Puma Biotechnology
$38.05

1.35 (3.68%)

11/14/16
JPMS
11/14/16
NO CHANGE
JPMS
Puma Biotechnology selloff today an overreaction, says JPMorgan
JPMorgan analyst Cory Kasimov views the selloff today in shares of Puma Biotechnology as an overreaction. The diarrhea rates included in abstract posted today are worse than the last update, but the rates are equivalent to a median number of around 1 episode per patient in the first cycle of treatment, Kasimov tells investors in an intraday research note. He continues to consider neratinib an approvable drug based on currently available data.
11/14/16
STFL
11/14/16
NO CHANGE
Target $88
STFL
Buy
Stifel calls Puma selloff overdone, but concerned by management comments
Stifel analyst Thomas Shrader views the intraday selloff in Puma Biotechnology shares as an overreaction, but he calls management's comments last week "an issue." At a conference last week, management said, "In December, we showed the interim results of this and as you can see the grade 3 diarrhea ranged from 13% to 18%. And also, all of the things that would be involved in tolerability, like stopping the drug, reducing the drug, or discontinuing were all brought down as well. Here, you can see the diarrhea over time in the control study." Shrader believes today's abstract was likely embargoed, but he still finds last week's comments "strange." Nonetheless, the analyst feels neratinib's Grade 3 diarrhea rate is manageable and he notes that Grade 4 diarrhea events were zero in all arms of the trial. Shrader has a Buy rating on Puma with an $88 price target.
01/03/17
SBSH
01/03/17
NO CHANGE
Target $88
SBSH
Buy
Citi finds 'bullish' Youtube videos for Puma cancer drug
Two new "Key Opinion Leader" videos expressing continued optimism on Puma Biotechnology's breast cancer drug neratinib posted on Youtube within the last several weeks, Citi analyst Yigal Nochomovitz tells investors in a research note. Similar to two videos posted in August, the new videos have received very little online attention with 25-30 views, the analyst contends. Nochomovitz believes Key Opinion Leader interest in neratinib continues to accelerate. The analyst notes a doctor in one of the videos said the chances of getting "significant diarrhea go way, way down" after a month. He keeps a Buy rating on Puma shares with an $88 price target. The stock closed Friday up 15c to $30.70.
02/01/17
SBSH
02/01/17
NO CHANGE
Target $88
SBSH
Buy
Citi sees Puma doubling if Roche study is negative
Citi analyst Yigal Nochomovitz believes shares of Puma Biotechnology (PBYI) could rally 100% or more if Roche (RHHBY) reports a negative Phase III Aphinity study readout of Perjeta in the adjuvant treatment of HER2-positive early breast cancer. The analyst, which notes Roche slides today point to a data readout in late February or early March, sees maximum downside for Puma shares of 30% should Aphinity succeed. A selloff would be a "very good opportunity to buy the dip" as despite the controversy around neratinib's benefit/risk profile, neratinib should be approved by the FDA for extended adjuvant, Nochomovitz tells investors in a research note. The FDA action date for neratinib is in July. The analyst adds that recent stock sales by Puma management were in the context of tax obligations required for vesting of restricted stock units. Management's net ownership in the company has actually increased with the vesting of a tranche of restricted stock, Nochomovitz writes. He has a Buy rating on Puma with an $88 price target. The stock is unchanged at $32.40 in morning trading.

TODAY'S FREE FLY STORIES

ENIA

Enel Americas

$9.25

-0.08 (-0.86%)

19:01
06/17/18
06/17
19:01
06/17/18
19:01
Upgrade
Enel Americas rating change  »

Enel Americas upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UL

Unilever; also tag UN

$54.26

0.64 (1.19%)

, UN

Unilever; also tag UL

$54.74

0.7 (1.30%)

18:55
06/17/18
06/17
18:55
06/17/18
18:55
Periodicals
Unilever taking stand against digital media's fake followers, Reuters says »

Unilever, the…

UL

Unilever; also tag UN

$54.26

0.64 (1.19%)

UN

Unilever; also tag UL

$54.74

0.7 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$98.91

(0.00%)

, CMCSA

Comcast

$33.85

0.03 (0.09%)

16:58
06/17/18
06/17
16:58
06/17/18
16:58
Hot Stocks
Box Office Battle: 'Incredibles 2' breaks record with $180M »

Disney (DIS) and…

TWX

Time Warner

$98.91

(0.00%)

CMCSA

Comcast

$33.85

0.03 (0.09%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$49.11

-0.02 (-0.04%)

FOX

21st Century Fox

$44.57

0.14 (0.32%)

FOXA

21st Century Fox

$44.60

0.03 (0.07%)

LGF.A

Lionsgate

$26.57

1.52 (6.07%)

DIS

Disney

$108.91

0.15 (0.14%)

VIAB

Viacom

$29.40

0.49 (1.69%)

VIA

Viacom

$33.95

0.15 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

OAS

Oasis Petroleum

$12.01

-0.63 (-4.98%)

, OMP

Oasis Midstream Partners

$17.29

-1.02 (-5.57%)

16:46
06/17/18
06/17
16:46
06/17/18
16:46
Conference/Events
JPMorgan to hold a conference »

3rd Annual Energy Equity…

OAS

Oasis Petroleum

$12.01

-0.63 (-4.98%)

OMP

Oasis Midstream Partners

$17.29

-1.02 (-5.57%)

SRCE

1st Source

$55.36

0.13 (0.24%)

LGCY

Legacy Reserves

$6.07

-0.03 (-0.49%)

EVA

Enviva

$29.35

0.15 (0.51%)

CRC

California Resources

$35.03

-2.57 (-6.84%)

INSM

Insmed

$26.74

-1.5 (-5.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 28

    Sep

16:43
06/17/18
06/17
16:43
06/17/18
16:43
Conference/Events
Leerink to hold a tour »

Ribs N' Bones Bus…

16:40
06/17/18
06/17
16:40
06/17/18
16:40
Conference/Events
Citigroup to hold a conference »

2018 European Healthcare…

GM

General Motors

$43.91

0.32 (0.73%)

, FCAU

Fiat Chrysler

$20.86

-0.37 (-1.74%)

16:38
06/17/18
06/17
16:38
06/17/18
16:38
Periodicals
Automakers putting smaller engines into big trucks, WSJ reportsFord »

U.S. auto makers are…

GM

General Motors

$43.91

0.32 (0.73%)

FCAU

Fiat Chrysler

$20.86

-0.37 (-1.74%)

F

Ford

$11.88

-0.01 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

MSFT

Microsoft

$100.24

-1.14 (-1.12%)

, GOOGL

Alphabet Class A

$1,159.03

-1.08 (-0.09%)

16:34
06/17/18
06/17
16:34
06/17/18
16:34
Periodicals
Microsoft is fixing office, WSJ reports »

The new version of…

MSFT

Microsoft

$100.24

-1.14 (-1.12%)

GOOGL

Alphabet Class A

$1,159.03

-1.08 (-0.09%)

GOOG

Alphabet

$1,151.95

-0.05 (-0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 28

    Oct

16:34
06/17/18
06/17
16:34
06/17/18
16:34
Conference/Events
Deutsche Bank to hold a conference »

Taiwan Auto Electronics…

WFC

Wells Fargo

$54.99

0.23 (0.42%)

, MS

Morgan Stanley

$51.17

-0.12 (-0.23%)

16:33
06/17/18
06/17
16:33
06/17/18
16:33
Conference/Events
Federal Reserve Bank of New York to hold a conference »

Reforming Culture &…

WFC

Wells Fargo

$54.99

0.23 (0.42%)

MS

Morgan Stanley

$51.17

-0.12 (-0.23%)

BAC

Bank of America

$29.27

-0.24 (-0.81%)

C

Citi

$66.34

0.18 (0.27%)

WBK

Westpac Banking

$20.67

0.125 (0.61%)

GS

Goldman Sachs

$232.00

-1.695 (-0.73%)

BCS

Barclays

$10.59

-0.225 (-2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 19

    Jun

  • 21

    Jun

  • 22

    Jun

  • 13

    Jul

  • 10

    Sep

  • 14

    Jan

  • 12

    Apr

  • 15

    Apr

  • 13

    Jul

  • 16

    Jul

  • 15

    Oct

  • 15

    Oct

F

Ford

$11.88

-0.01 (-0.08%)

16:25
06/17/18
06/17
16:25
06/17/18
16:25
Hot Stocks
Ford acquires Michigan Central Station »

Ford Motor has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$54.81

1.165 (2.17%)

16:22
06/17/18
06/17
16:22
06/17/18
16:22
Hot Stocks
Bristol-Myers' ELOQUENT-3 trial meets primary endpoint »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 10

    Jul

PTCT

PTC Therapeutics

$37.57

-0.75 (-1.96%)

, RHHBY

Roche

$0.00

(0.00%)

16:18
06/17/18
06/17
16:18
06/17/18
16:18
Hot Stocks
PTC Therapeutics presents updated preliminary data from SMA FIREFISH Program »

PTC Therapeutics (PTCT)…

PTCT

PTC Therapeutics

$37.57

-0.75 (-1.96%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$9.95

0.5 (5.29%)

16:15
06/17/18
06/17
16:15
06/17/18
16:15
Hot Stocks
Cytokinetics announces data from Phase 2 clinical study of Reldesemtiv in SMA »

Cytokinetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PERY

Perry Ellis

$27.92

0.31 (1.12%)

16:12
06/17/18
06/17
16:12
06/17/18
16:12
Hot Stocks
Perry Ellis enters into $437M transaction to become private company »

Perry Ellis International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSTM

Verastem

$6.53

0.95 (17.03%)

16:08
06/17/18
06/17
16:08
06/17/18
16:08
Hot Stocks
Verastem presents duvelisib data at EHA 2018 annual meeting »

Verastem announced one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

IQ

iQIYI

$40.16

-0.44 (-1.08%)

16:05
06/17/18
06/17
16:05
06/17/18
16:05
Hot Stocks
iQIYI obtains broadcasting rights for all four golf majors »

iQIYI announced it had…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$200.55

0.86 (0.43%)

15:56
06/17/18
06/17
15:56
06/17/18
15:56
Conference/Events
Home Depot participates in a field trip with UBS »

Field Trip to Atlanta, GA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAY

Verifone

$22.84

0.01 (0.04%)

15:28
06/17/18
06/17
15:28
06/17/18
15:28
Conference/Events
Verifone to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CACI

CACI

$167.60

1.1 (0.66%)

14:18
06/17/18
06/17
14:18
06/17/18
14:18
Conference/Events
CACI to hold a webcast »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

ARGX

Argenx

$92.38

-3.32 (-3.47%)

14:11
06/17/18
06/17
14:11
06/17/18
14:11
Conference/Events
Argenx to hold a KOL breakfast symposium »

Management holds a Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

PTC

PTC

$94.87

-0.46 (-0.48%)

14:06
06/17/18
06/17
14:06
06/17/18
14:06
Conference/Events
PTC to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:41
06/17/18
06/17
13:41
06/17/18
13:41
Conference/Events
Federal Reserve Bank of Atlanta president speaks at a meeting »

Atlanta Federal Reserve…

VRX

Valeant

$26.86

0.06 (0.22%)

13:31
06/17/18
06/17
13:31
06/17/18
13:31
Conference/Events
Breaking Conference/Events news story on Valeant »

FDA PDUFA Date for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 27

    Aug

WMGI

Wright Medical

$25.83

-0.26 (-1.00%)

13:27
06/17/18
06/17
13:27
06/17/18
13:27
Conference/Events
Wright Medical management to meet with Leerink »

Meeting to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.